ZA200703059B - 6-Amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor - Google Patents
6-Amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorInfo
- Publication number
- ZA200703059B ZA200703059B ZA200703059A ZA200703059A ZA200703059B ZA 200703059 B ZA200703059 B ZA 200703059B ZA 200703059 A ZA200703059 A ZA 200703059A ZA 200703059 A ZA200703059 A ZA 200703059A ZA 200703059 B ZA200703059 B ZA 200703059B
- Authority
- ZA
- South Africa
- Prior art keywords
- aza
- dopamine
- receptor
- respond
- modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61874304P | 2004-10-14 | 2004-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200703059B true ZA200703059B (en) | 2008-09-25 |
Family
ID=35482313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200703059A ZA200703059B (en) | 2004-10-14 | 2007-04-13 | 6-Amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7759397B2 (xx) |
| EP (2) | EP1807392A1 (xx) |
| JP (1) | JP5193601B2 (xx) |
| KR (1) | KR101300046B1 (xx) |
| CN (1) | CN101039900B (xx) |
| AU (1) | AU2005293693B2 (xx) |
| BR (1) | BRPI0516529A (xx) |
| CA (1) | CA2583967C (xx) |
| IL (1) | IL182430A (xx) |
| MX (1) | MX2007004355A (xx) |
| NZ (1) | NZ555121A (xx) |
| TW (1) | TWI382013B (xx) |
| WO (1) | WO2006040177A1 (xx) |
| ZA (1) | ZA200703059B (xx) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CN105992764A (zh) | 2013-10-17 | 2016-10-05 | 艾伯维德国有限责任两合公司 | 氨基色满、氨基硫代色满及氨基-1,2,3,4-四氢喹啉衍生物，包含其的药物组合物及其在治疗中的用途 |
| WO2015055771A1 (en) | 2013-10-17 | 2015-04-23 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2703688B1 (fr) | 1993-04-09 | 1995-05-19 | Rhone Poulenc Chimie | Réactif de désallylation, procédé de désallylation utilisant ledit réactif. |
| ES2139750T3 (es) * | 1993-08-06 | 2000-02-16 | Upjohn Co | 2-aminoindanos como ligandos selectivos d3 de la dopamina. |
| AU707091B2 (en) * | 1995-02-01 | 1999-07-01 | Pharmacia & Upjohn Company | 2-aminoindans as selective dopamine D3 ligands |
| ATE232894T1 (de) | 1996-05-30 | 2003-03-15 | Baker Hughes Inc | Naphtensäurekorrosionskontrolle mit thiophosphorverbindungen |
| DE69724259T2 (de) | 1996-05-31 | 2004-06-09 | Pharmacia & Upjohn Co., Kalamazoo | Arylsubstituierte cyclische amine als selektive dopamin-d3-liganden |
| DE19922443A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen |
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
-
2005
- 2005-10-14 KR KR1020077010956A patent/KR101300046B1/ko not_active IP Right Cessation
- 2005-10-14 EP EP05800575A patent/EP1807392A1/en not_active Withdrawn
- 2005-10-14 US US11/665,420 patent/US7759397B2/en not_active Expired - Fee Related
- 2005-10-14 BR BRPI0516529-6A patent/BRPI0516529A/pt not_active Application Discontinuation
- 2005-10-14 JP JP2007536104A patent/JP5193601B2/ja not_active Expired - Fee Related
- 2005-10-14 MX MX2007004355A patent/MX2007004355A/es active IP Right Grant
- 2005-10-14 TW TW094135920A patent/TWI382013B/zh not_active IP Right Cessation
- 2005-10-14 EP EP10183356A patent/EP2311801A1/en not_active Withdrawn
- 2005-10-14 WO PCT/EP2005/011090 patent/WO2006040177A1/en active Application Filing
- 2005-10-14 NZ NZ555121A patent/NZ555121A/en not_active IP Right Cessation
- 2005-10-14 CA CA2583967A patent/CA2583967C/en not_active Expired - Fee Related
- 2005-10-14 CN CN2005800347904A patent/CN101039900B/zh not_active Expired - Fee Related
- 2005-10-14 AU AU2005293693A patent/AU2005293693B2/en not_active Ceased
-
2007
- 2007-04-10 IL IL182430A patent/IL182430A/en not_active IP Right Cessation
- 2007-04-13 ZA ZA200703059A patent/ZA200703059B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL182430A (en) | 2011-10-31 |
| KR20070069203A (ko) | 2007-07-02 |
| TWI382013B (zh) | 2013-01-11 |
| CA2583967A1 (en) | 2006-04-20 |
| IL182430A0 (en) | 2007-07-24 |
| CN101039900B (zh) | 2012-03-21 |
| CA2583967C (en) | 2013-07-23 |
| AU2005293693A1 (en) | 2006-04-20 |
| BRPI0516529A (pt) | 2008-09-09 |
| EP1807392A1 (en) | 2007-07-18 |
| AU2005293693A2 (en) | 2006-04-20 |
| JP5193601B2 (ja) | 2013-05-08 |
| TW200628437A (en) | 2006-08-16 |
| US7759397B2 (en) | 2010-07-20 |
| AU2005293693B2 (en) | 2011-11-17 |
| JP2008516913A (ja) | 2008-05-22 |
| MX2007004355A (es) | 2007-07-17 |
| WO2006040177A1 (en) | 2006-04-20 |
| US20080318996A1 (en) | 2008-12-25 |
| KR101300046B1 (ko) | 2013-08-30 |
| NZ555121A (en) | 2011-01-28 |
| EP2311801A1 (en) | 2011-04-20 |
| CN101039900A (zh) | 2007-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200703059B (en) | 6-Amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| PT1833799E (pt) | Derivados de 3-fenil-pirazole como moduladores do receptor 5-ht2a de serotonina úteis no tratamento de desordens que lhe estão relacionadas | |
| HRP20141209T1 (hr) | Modulatori receptora prostaciklina (pgi2) korisni za lijeäśenje poremeä†aja povezanih s time | |
| ZA200608628B (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
| PL2370413T3 (pl) | Modulatory receptora prostacykliny (PGI2) użyteczne w leczeniu zaburzeń z nimi związanych | |
| IL185016A0 (en) | Compounds for the treatment of proliferative disorders | |
| HK1143588A1 (zh) | 適合用於治療對血清素 受體調節有反應的病症的多種喹啉化合物 | |
| HRP20130360T1 (hr) | Sredstva za prevenciju i lijeäśenje poremeä†aja koji obuhvaä†aju modulaciju ryr receptora | |
| WO2009137843A9 (en) | Nmda receptor antagonists for the treatment of neuropsychiatric disorders | |
| IL179609A0 (en) | Imidazole variants as modulators of gaba receptor for the treatment of gi disorders | |
| HK1208802A1 (en) | Modulation of the vps10p-domain receptors for the treatment of cardiovascular disease vps10p- | |
| PL1841433T3 (pl) | Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego | |
| IL201107A0 (en) | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| IL225745A0 (en) | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds are suitable for the treatment of disorders that respond to dopamine 3d receptor regulation | |
| ZA200705008B (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| HK1139933A1 (en) | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| HK1146628A1 (en) | 1,2,4,-triazin-3,5-dione compounds for treating disorders that respond to modulation of the dopamine d3 receptor | |
| IL189524A0 (en) | Imidazole compounds for the treatment of neurological disorders | |
| ZA201003594B (en) | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
| ZA200703885B (en) | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | |
| GB0724947D0 (en) | Composition for the treatment of psychiatric disorders |